Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer - Takeaways - MDSpire

Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer

  • By

  • Zeynep Irem Ozay

  • Yeonjung Jo

  • Georges Gebrael

  • Micah Ostrowski

  • Vinay Mathew Thomas

  • Haoran Li

  • Ryon P. Graf

  • Soumyajit Roy

  • Benjamin L. Maughan

  • Avirup Guha

  • Irbaz Bin Riaz

  • Emmanuel S. Antonarakis

  • Rana R. McKay

  • Neeraj Agarwal

  • Umang Swami

  • June 24, 2026

  • 0 min

Share

  • 1

    Bone metastases affect over 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) and increase the risk of skeletal-related events.

  • 2

    Bone-modifying agents (BMAs) like denosumab and zoledronic acid can reduce skeletal-related events in mCRPC, yet their use remains underreported.

  • 3

    In a cohort study of 14,076 mCRPC patients, 56.6% received BMAs, with a median time from diagnosis to initiation of 39 days.

  • 4

    BMA use decreased over time, with denosumab usage declining and zoledronic acid usage increasing from 2013 to 2024.

  • 5

    43.4% of patients in the study did not receive BMAs, indicating a gap between clinical guidelines and actual practice.

Original Source(s)

Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer

  • by Zeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, Micah Ostrowski, Vinay Mathew Thomas, Haoran Li, Ryon P. Graf, Soumyajit Roy, Benjamin L. Maughan, Avirup Guha, Irbaz Bin Riaz, Emmanuel S. Antonarakis, Rana R. McKay, Neeraj Agarwal, Umang Swami

  • June 24, 2026

Related Content

Correction: MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances

Outcomes of malignant orbital tumors: a 22-year Norwegian single-center series

Case Report: Metastatic pancreatic ductal adenocarcinoma initially masked by multiple gastroduodenal ulcers with apparent endoscopic healing: a diagnostic pitfall